TLR9 and cancer: However, the HCQ–sorafenib combination reduced TLR9 expression, downregulated the expression of cancer stem genes, and enhanced the antitumor efficacy of sorafenib by inducing SOD1 expression and reducing oxidative DNA damage and apoptosis-associated genes in sorafenib-resistant HCC cells via the has-miR-30a-5p axis.